Key Highlights
- Net loss was USD 23.5 million for the third quarter of 2026.
- Research and development expenses fell USD 4.4 million to USD 18.1 million.
- Cash, cash equivalents and investments were USD 174.1 million.
- The January private Placement delivered net proceeds of about USD 126.4 million.
Century Therapeutics (NASDAQ:IPSC) reported a third-quarter 2026 net loss of USD 23.5 million, with loss per share of USD 0.11, against an estimate of USD 0.12. For the nine months, net loss was USD 79.6 million. The company is a biotechnology company developing iPSC-derived cell therapy products for type 1 diabetes and other autoimmune diseases. Its islet replacement and CAR-T programs are allogeneic, meaning they are derived from healthy donors for use in any patient.
Spending and Cost Changes
Research and development expenses were USD 18.1 million for the quarter, against USD 22.5 million a year earlier. The decrease of USD 4.4 million was partly offset by an increase of USD 0.3 million in research and laboratory expenses. The filing attributes it mainly to a USD 1.7 million decrease in personnel costs from a reduction in Research and Development staff, and a USD 3.1 million decrease in Facility and other allocated costs tied to portfolio prioritization.
General and administrative expenses were USD 7.1 million, against USD 6.8 million. The filing attributes the increase mainly to a gain on Lease modification in the prior year. Impairment of long-lived Assets was zero, against USD 6.8 million a year earlier, when the company took a charge on part of its Philadelphia headquarters.
Cash Flow and Funding
As of September 30, 2026, the company had cash and cash equivalents of USD 45.0 million and investments of USD 129.1 million, totaling USD 174.1 million. Net cash used in Operating Activities for the nine months was USD 67.3 million. The filing links it to a net loss of USD 79.6 million and a decrease of USD 8.2 million in net operating assets and liabilities, offset by non-cash charges of USD 20.5 million.
The non-cash charges consisted primarily of a loss on the terminated lease component of USD 11.1 million, USD 7.8 million of Depreciation expense, USD 4.8 million of stock-based compensation and USD 0.9 million of non-cash operating lease expense. They were partly offset by a USD 3.8 million change in Fair Value of contingent consideration.
Net cash used in investing activities was USD 77.3 million for the nine months, against net cash provided of USD 85.1 million a year earlier. Financing activities consisted primarily of USD 126.4 million in proceeds from the 2026 private placement.
The 2026 Private Placement
The private placement closed on January 9, 2026. The company issued 92,030,595 shares of common stock with accompanying warrants to purchase 58,695,648 shares, or pre-funded warrants in lieu thereof. It also issued pre-funded warrants to purchase up to 25,360,704 shares, with accompanying warrants to purchase 12,680,352 shares, at an exercise price of USD 0.0001 per pre-funded warrant. Net proceeds were approximately USD 126.4 million.
The company states that it intends to use the net proceeds to fund development of its lead product candidate, CNTY-813, and for Working Capital and general corporate purposes. A Warrant provision refers to a period 30 days after public announcement of initial Phase 1 clinical data for CNTY-813 or, if earlier, the third anniversary of closing.
The filing states that management recognizes the need to raise additional capital to fully implement its business plan. For the nine months ended September 30, 2025, the company recorded Net Income of USD 9.6 million, with non-cash charges of USD 20.3 million.
The reported items are the net loss of USD 23.5 million, research and development expenses of USD 18.1 million, cash and investments of USD 174.1 million and the proceeds from the private placement. The company is listed on the Nasdaq Capital Market.




_11_19_2026_18_08_46_525309.jpg)

Please wait processing your request...